Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

334.03
Delayed Data
As of Apr 22
 +0.69 / +0.21%
Today’s Change
281.89
Today|||52-Week Range
442.00
-10.57%
Year-to-Date
Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
Apr 16 / Zacks.com - Paid Partner Content
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
Apr 15 / Zacks.com - Paid Partner Content
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
Apr 16 / Zacks.com - Paid Partner Content
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
Apr 11 / Zacks.com - Paid Partner Content
Is Alnylam Pharmaceuticals a Buy Now?
Apr 16 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
Apr 10 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close333.34
Today’s open332.50
Day’s range329.00 - 336.00
Volume921,746
Average volume (3 months)751,227
Market cap$35.8B
Data as of 4:00pm ET, 04/22/2019

Growth & Valuation

Earnings growth (last year)+100.98%
Earnings growth (this year)+0.98%
Earnings growth (next 5 years)+11.00%
Revenue growth (last year)+14.28%
P/E ratio15.7
Price/Sales6.39
Price/Book4.15

Competitors

 Today’s
change
Today’s
% change
BAXBaxter International...+0.92+1.24%
VRTXVertex Pharmaceutica...+0.36+0.21%
ALXNAlexion Pharmaceutic...+2.95+2.34%
AGNAllergan-0.05-0.04%
Data as of 4:15pm ET, 04/22/2019

Financials

Next reporting dateMay 7, 2019
EPS forecast (this quarter)$5.41
Annual revenue (last year)$6.7B
Annual profit (last year)$2.4B
Net profit margin36.42%

Profile

Sector
Health Technology
Industry
Biotechnology
Co-President, Chief Executive Officer &
Director
Leonard S. Schleifer
Co-President, Director &
Chief Scientific Officer
George Damis Yancopoulos
Corporate headquarters
Tarrytown, New York

Forecasts